Rockefeller Capital Management
QNCX icon

Rockefeller Capital Management’s Quince Therapeutics QNCX Stock Holding History

Rockefeller Capital Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-848
Closed -$280K – 4441
2025
Q2 		$280K Buy
+848
New +$194K ﹤0.01% 1664
2021
Q4 		– Sell
-5
Closed -$91K – 3956
2021
Q3 		$91K Hold
5
– – ﹤0.01% 1901
2021
Q2 		$53K Hold
5
– – ﹤0.01% 2049
2021
Q1 		$36K Buy
+5
New +$36K ﹤0.01% 2033

Other funds holding QNCX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Rockefeller Capital Management's QNCX Position: Q3 2025 in Review

Rockefeller Capital Management sold out of Quince Therapeutics (QNCX) in Q3 2025, closing a stake of 848 shares — an estimated $280K sold.

Rockefeller Capital Management first reported a position in QNCX in Q1 2021 and held it in 4 quarters. The position peaked at $280K in Q2 2025. 41 funds tracked by Wall St. Rank hold QNCX as of Q3 2025.

  • Rockefeller Capital Management reported no remaining Quince Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Rockefeller Capital Management sold 848 Quince Therapeutics shares in Q3 2025, an estimated $280K.
  • Rockefeller Capital Management first reported a position in Quince Therapeutics in Q1 2021 and held it in 4 quarters.
  • Rockefeller Capital Management's Quince Therapeutics position peaked at $280K in Q2 2025.
  • 41 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2025.

Based on Rockefeller Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.